New combo therapy shows promise for lymphoma in seniors
NCT ID NCT00690560
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a treatment plan for adults aged 65 to 80 with a type of lymphoma (large B-cell). The plan combined standard chemotherapy with targeted antibodies and a radioactive drug. The goal was to see if this approach could better control the cancer. The study involved 30 participants and found that most responded well, though some had side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Antoine Lacassagne
Nice, 06189, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Can a drug duo outsmart resistant lymphomas?
- New PET tracer could sharpen diagnosis of blood cancers
- 10,000 DNA samples could reveal hidden genetic triggers for leukemia and lymphoma
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma
- New dashboard aims to make leukemia trials more inclusive